Sorting out Mushroom extracts
A common question we are asked involves the differences between our various mushroom extracts. For the most part, the differences involve slight variations in beta-d-glucan concentration, current applications and/or traditional use.
Pure Encapsulations Maitake Mushroom is a 4:1 extract providing about 3% beta glucan. Maitake has demonstrated the potential to support immune function, cellular health, cardiovascular function, and healthy glucose and lipid metabolism. (1-4). Traditionally, maitake was used as a tonic and adaptogen and for promoting wellness and vitality (13). *
Maitake D-Fraction® is a specialized extract of maitake standardized to contain 30% D-fraction. At a 1995 symposium in Tampa, FL, clinical reports involving 165 subjects in Japan were presented. Results suggested that Maitake D-fraction may provide high potential support for the liver, lung, breast and brain. A clinical trial evaluating Maitake D-fraction for breast and prostate health is currently underway (11).*
Reishi mushroom extract contains approximately 10% beta glucan. Similar to maitake, preliminary studies suggest that reishi has been positively associated with cardiovascular health and immune support (5-7). Recent studies indicate that reishi may support healthy cellular function for the breast and prostate (8). Reishi may also play a hepatoprotective role, attributed in part to its superoxide scavenging ability (9, 10). Traditional uses of reishi include support for general fatigue and weakness (13).*
Shiitake is composed of about 4-5% beta glucan and a unique polysaccharide known as lentinan. Studies using high dose lentinan preparations report promising immune and liver support potential (12). For thousands of years, shiitake was used by various cultures for immune support and to increase energy (13).*
Pure Encapsulations mushroom extracts include: Maitake Mushroom extract, Maitake D-Fraction, Reishi mushroom extract, Shiitake Mushroom extract and
M/R/S Mushroom Formula, a combination of maitake, reishi and shiitake for broad spectrum support.
Maitake D-Fraction® is a registered trademark of Maitake Products, Inc., Paramus, NJ
References:
1.) Yamada Y, Nanba H, Kuroda H. Antitumor effect of orally administered extracts from fruit body of Grifola frondosa (maitake). Chemotherapy 1990;38:790Ð6.
2.) Nanba H. Immunostimulant activity in vivo and anti-HIV activity in vitro of 3 branched b-1Ð6-glucans extracted from maitake mushrooms (Grifola frondosa). VIII International Conference on AIDS, Amsterdam, 1992 [abstract].
3.) Kubo K, Nanba H. Anti-hyperliposis effect of maitake fruit body (Grifola frondosa). I. Biol Pharm Bull 1997;20:781Ð5.
4.) Adachi K, Nanba H, Otsuka M, Kuroda H. Blood pressure lowering activity present in the fruit body of Grifola frondosa (maitake). Chem Pharm Bull 1988;36:1000Ð6.
5.) Kammatsuse K, Kajiware N, Hayashi K. Studies on Ganoderma lucidum: I. Efficacy against hypertension and side effects. Yakugaku Zasshi 1985;105:531Ð3.
6.) Jin H, Zhang G, Cao X, et al. Treatment of hypertension by ling zhi combined with hypotensor and its effects on arterial, arteriolar and capillary pressure and microcirculation. In: Nimmi H, Xiu RJ, Sawada T, Zheng C (eds). Microcirculatory Approach to Asian Traditional Medicine. New York: Elsevier Science, 1996:131Ð8.
7.) Jones K. Reishi mushroom: Ancient medicine in modern times. Alt Compl Ther 1998;4(4):256Ð66 [review].
8.) Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NW. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 2002 Nov 8;298(4):603-12.
9.) Zhang GL, Wang YH, Ni W, Teng HL, Lin ZB. Hepatoprotective role of Ganoderma lucidum polysaccharide against BCG-induced immune liver injury in mice. World J Gastroenterol 2002 Aug;8(4):728-33.
10.) Shieh Yh et al. Evaluation of the hepatic and renal-protective effects of Ganoderma lucidum in mice. Am J Chin Med 2001;29(3-4):501-7.
11.) Preuss, HG. Konno S. Maitake Magic. Freedom Press 2002.
12.) Gordon M et al. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J Med 1998;29(5-6):305-30.
13.) www.purecaps.com/HealthLibrary/ClinicalEssentials
For educational purposes only. Consult your physician for any health problems.
*This is a statement of nutritional support. This statement has not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
|
